AI assistant
NEKTAR THERAPEUTICS — Director's Dealing 2016
Sep 23, 2016
32134_dirs_2016-09-23_d6cad171-61ab-4460-8b0d-a41e2e7295e2.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: NEKTAR THERAPEUTICS (NKTR)
CIK: 0000906709
Period of Report: 2016-09-21
Reporting Person: CHESS ROBERT (Director)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2016-09-21 | Common Stock | A | 8000 | $0.00 | Acquired | 271623 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2016-09-21 | Stock Option | $19.15 | A | 20000 | Acquired | 2024-09-20 | Common Stock (20000) | Direct |
Footnotes
F1: This stock award was acquired pursuant to a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive, upon vesting of the unit, one share of the issuer's common stock.
F2: This restricted stock unit award vests in full, one year following September 21, 2016.
F3: This number includes 4,914 shares held by the reporting person in the Issuer's 401(k) plan. The acquisition of these shares under that plan is exempt under Rule 16b-3(c).
F4: This option vests in equal monthly installments over the one-year period beginning on September 30, 2016.